One-year effectiveness and safety of ustekinumab treatment in patients with ulcerative colitis: an Asan-Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD) multicenter real-world cohort study

Key Points

• Evaluate the effectiveness and safety of ustekinumab in treating ulcerative colitis over one year.
• Real-world cohort study design
• Multicenter data collection from Daegu-Gyeongbuk region
• Analysis of patient outcomes after treatment with ustekinumab
• Ustekinumab demonstrated favorable effectiveness over a year
• Safety profile was acceptable for Korean patients with ulcerative colitis